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Abstract  
Metformin (dimethyl biguanide) has become the preferred first-line oral blood glucose-lowering 
agent to manage type 2 diabetes.  Its history is linked to Galega officinalis (goat’s rue), a traditional 
herbal medicine in Europe found to be rich in guanidine which, in 1918 was shown to lower blood 
glucose.  Guanidine derivatives, including metformin, were synthesised and some (not metformin) 
were used to treat diabetes in the 1920s and 1930s but were discontinued due to toxicity and the 
increased availability of insulin. Metformin was rediscovered in the search for antimalarial agents in 
the 1940s and during clinical tests proved useful to treat influenza when it sometimes lowered blood 
glucose.  This property was pursued by the French physician Jean Sterne who first reported the use 
of metformin to treat diabetes in 1957.  But metformin received limited attention as it was less 
potent than other glucose-lowering biguanides (phenformin and buformin), which were generally 
discontinued in the late 1970s due to high risk of lactic acidosis.  Metformin’s future was precarious -  
its reputation tarnished by association with other biguanides despite evident differences. The ability 
of metformin to counter insulin resistance and address adult-onset hyperglycaemia without weight 
gain or increased risk of hypoglycaemia gradually gathered credence in Europe, and after intensive 
scrutiny metformin was introduced into the USA in 1995. Long-term cardiovascular benefits of 
metformin were identified by the United Kingdom Prospective Diabetes Study in 1998, providing a 
new rationale to adopt metformin as initial therapy.  Sixty years after its introduction to treat 
diabetes metformin has become the most prescribed glucose-lowering medicine worldwide with the 
potential for further therapeutic applications.    [263 words]      
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Introduction 
This short biography of metformin (dimethyl biguanide) plots a chequered history from herbal 
ancestry in Europe to synthesis and discovery of glucose-lowering activity in the 1920s  -  
information that was disregarded and forgotten. In the 1940s metformin was rediscovered in the 
search for antimalarial agents and repurposed to treat influenza before its introduction in 1957 to 
treat adult-onset diabetes (Table 1).  But metformin was considered weaker than other glucose-
lowering biguanides and received limited use. When the other biguanides (phenformin and 
buformin) were withdrawn in the late 1970s due to lactic acidosis, metformin was spared but mostly 
rejected.  However, ongoing research and minimal clinical use in the 1980s and early 1990s 
demonstrated a uniqueness and utility of metformin that fostered its rescue.  Introduction of 
metformin into the USA in 1995 boosted research and clinical use, and long-term evidence from the 
United Kingdom Prospective Diabetes Study (UKPDS) in 1998 set metformin on course for its current 
position as preferred initial agent to manage hyperglycaemia in type 2 diabetes.  Now exonerated, 
metformin is being assessed for further clinical indications.  How could such a medicinal servant 
have received such a tempestuous journey? 
Herbal history 
The herbal lineage of metformin can be traced from the use of Galega officinalis (goat’s rue, French 
lilac, Italian fitch, Spanish sainfoin, professor weed) as a traditional medicine in medieval Europe 
(Figure 1) [1].  Also known as Herba rutae caprariae in some herbals, G. officinalis was ascribed 
benefits against worms, epilepsy (falling-sickness), fever and pestilence in Culpeper’s Complete 
Herbal of 1653, but in Hill’s The Vegetable System of 1772 Galega was recommended to treat 
conditions of thirst and frequent urination [2-4].  Wild G. officinalis was widely recognised in Europe 
as an animal galactagogue from which it gained its name (from the Greek for milk stimulant).  The 
plant was introduced into North America in 1891 and is classed as a noxious weed in many states of 
the USA [5].  Chemical analyses of G. officinalis dating from the mid-1800s found the plant to be rich 
in guanidine and related compounds, especially the immature seed pods (Figure 2) [6].  In 1918 
guanidine was reported to reduce blood glucose in animals, and during the 1920s several mono-
guanidine derivatives, notably galegine (isoamylene guanidine) and diguanidines such as synthalin 
(two guanidines separated by a methylene chain) were also shown to lower blood glucose in animals 
[6- 10].  This led to the introduction of galegine and the more potent synthalin as treatments for 
diabetes, but initial optimism was tempered with disappointment as toxicity was observed, curtailing 
their use during the 1930s as insulin became more widely available [6, 11-15].   
From Galega to biguanides 
The chemical origins of metformin run in parallel with the herbal origins and date from the 
preparation of guanidine by Strecker (1840s -1860s) and the fusion of two guanidines into biguanide 
by Rathke in 1879  (Figure 2) [6, 16].  These provide the background to the synthesis of dimethyl 
biguanide by Werner and Bell in 1922 [17].  Despite structural proximity to the hypoglycaemic 
mono- and diguanidines, it was not until 1929 that metformin and other biguanides were reported 
to lower blood glucose in animals (rabbits and dogs) by Hesse and Taubmann and also by Slotta and 
Tschesche  [18, 19].  Metformin exerted least toxicity of the various methyl biguanides tested, and 
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biguanides were deemed to be less toxic than mono- and diguanidines [19].  But the real potential of 
these agents was underappreciated at the time due to the high doses required to achieve modest 
glucose lowering in non-diabetic animals (compared with subsequent evidence in diabetic models).  
So the biguanides were not developed as therapies for diabetes and became forgotten during the 
next decade along with the other guanidine-based agents.  
Rediscovery via malaria and influenza   
A third strand in the history of metformin is the independent development of a guanidine-based 
antimalarial agent proguanil (paludrine) in the mid 1940s, which was reported to cause a lowering of 
blood glucose in animal studies [20, 21].  Searching for other guanidine-based antimalarials, 
proguanil was modified to metformin, and during tests for antimalarial activity by Garcia in the 
Philippines in 1949 metformin was found to be helpful in treating a local influenza outbreak [22].  
This gave rise to metformin hydrochloride as an anti-influenza agent called flumamine, and a 
tendency for metformin to lower blood glucose in some of the influenza patients was duly noted [6, 
22].   
Step forward Jean Sterne 
The visionary who translated the antihyperglycaemic potential of metformin into a therapeutic 
reality was Jean Sterne, a physician at the Aron Laboratories in Suresnes in the west of Paris (Figure 
3).  In 1956, encouraged by laboratory owner Jan Aron, Sterne critically assessed the evidence 
around flumamine and recalled his involvement with a disappointing study of galegine as an intern 
with Professor Francis Rathery at l’Hopital de le Pitie in Paris many years earlier [23].   Maybe 
metformin would be better, and working at Aron Laboratories with pharmacist colleague Denise 
Duval the duo embarked on an ambitious programme of research into the pharmacodynamics of 
several guanidine-based compounds including metformin and phenformin in normal and diabetic 
animals.  Unknowingly they duplicated and extended studies with guanidine-based compounds from 
the 1920s, and noted afresh the issues of high dose, limited glucose-lowering and high toxicity.  They 
singled out metformin for study in the diabetes clinic based on its glucose-lowering efficacy and 
minimal adverse effects in normal and diabetic animals, coupled with the flumamine experience in 
humans [6].   
Sterne had a position at l’Hopital Laennec in Paris where he started metformin studies with his 
patients, and he persuaded Dr Elie Azerad at Hopital Beaujon in Clichy to collaborate.  Their initial 
studies, mostly with insulin-treated patients, included a mix of juvenile-onset and maturity-onset 
presentations of diabetes. The studies indicated that metformin could replace the need for insulin in 
some maturity–onset patients and reduce the insulin dose required by others, but did not eliminate 
the need for insulin in juvenile-onset patients [6].  They also noted no occurrence of frank 
hypoglycaemia (as had recently been reported with sulphonylureas) and little or no effect in non-
diabetic subjects.  This was enough for Sterne to publish a brief account of his findings in a Moroccan 
medical journal in 1957 [24].  This is now recognised as a landmark paper for the emergence of 
metformin as a diabetes therapy.  In this paper Sterne made the following prophetic remarks: 
“LA6023 [metformin] is ………. well tolerated, which, even after very prolonged administration, does 
not damage the organism. At low doses it is hypoglycaemic by mouth in the rabbit, chicken, rat, 
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guinea-pig, dog, alloxan-diabetic rabbit, and the diabetic human……………..and its ultimate place in 
the management of diabetes requires further study.“   
Later publications would elaborate details of the studies, which revealed Sterne’s insight, skill and 
persistence [25-31].   Sterne suggested the name ‘glucophage’ (glucose eater) which was adopted by 
Aron to market metformin, and Sterne played a prominent role in ongoing research and physician 
education to assist the introduction of metformin into clinical practice in Europe [6].   History might 
be tempted to consider the diabetes indication of metformin as serendipitous, but we must 
gratefully acknowledge Sterne’s sharp enquiring mind, his prodigious experimentation and his 
perceptive clinical sixth sense.    
The biguanide opportunity 
During the 1950s other groups investigated guanidine derivatives and the glucose-lowering 
properties of phenformin were rediscovered and published in 1957 by Ungar and colleagues in the 
USA, followed by buformin in 1958 by Beringer and colleagues in Germany  [32, 33].  A vast selection 
of guanidine derivatives was then synthesised and evaluated, but enthusiasm was dampened by 
lesser glucose-lowering efficacy in non-diabetic animals compared with agents that stimulate insulin 
secretion [34, 35].  However, studies in human maturity-onset diabetes indicated greater glucose-
lowering efficacy with phenformin than other biguanides and this agent gained global popularity as 
an alternative to sulphonylureas, especially in the USA [36-38].  Metformin and buformin were not 
introduced into the USA and received relatively minor use in Europe, although metformin became 
available in the UK in 1958 and Canada in 1972, and was championed in several respected diabetes 
clinics.  Buformin became available across Europe (but not UK) in the early 1960s, particularly in 
Germany, but remained in the shadow of phenformin [39, 40].   
Clinical experience with metformin in small studies and anecdotal accounts with maturity-onset 
patients typically portrayed modest efficacy but generally good tolerability, accepting the gastro-
intestinal incommode experienced by some patients [6, 41].  Large comparative trials, notably in 
Edinburgh, showed that metformin could achieve similar long-term glycaemic control to 
sulphonylureas, and without significant hypoglycaemia or weight gain [42-44].  Later studies noted 
that basal insulin concentrations were often lowered, consistent with the amelioration of insulin 
resistance, while lipid lowering and improved haemodynamics were evident in some patients [41, 
45].  The requirement for renal monitoring was consolidated, contraindications were appreciated 
and a possible decrease of vitamin B12 absorption was recognised [41, 45].   
Lactic acidosis 
The risk of lactic acidosis, especially with phenformin and buformin was evident from the outset, and 
the controversy was fuelled when phenformin was withdrawn from the University Group Diabetes 
Program (UGDP) trial in the USA in 1971 [46-48].  Phenformin was removed from the market in the 
USA in 1978, and phenformin and buformin were discontinued in much of Europe around this time, 
although both agents can still be obtained in some countries [49].   The incidence of lactic acidosis 
amongst users of metformin was much lower and most cases could be attributed to inappropriate 
use in contraindicated patients with chronically impaired renal function or cases of acute kidney 
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disease [47, 50, 51].  Moreover, in some studies it was debatable whether incidence rates of lactic 
acidosis with metformin were higher than background rates amongst maturity-onset patients.  
Nevertheless the reputation of metformin was tarnished by association with the other biguanides, 
and metformin teetered on the very brink of discontinuation [49].    
Ironically soon after withdrawal of phenformin it was noted that about 9% of Europids have a 
mutation of the CYP2D6 hydroxylation enzyme, causing build-up of unmetabolized phenformin to 
precipitate lactic acidosis [52, 53]  - a problem that modern pharmacogenomics could deal with.  
How did metformin survive the biguanide cull? 
Clinical experience with metformin, albeit limited compared with phenformin, generally suggested a 
more favourable safety profile, and there were pharmacokinetic data to indicate distinct differences 
between metformin and the other biguanides (Figure 4; Table 2) [40, 41].  During the 1980s non-
insulin dependent diabetes (replacing the term maturity-onset) became viewed as much from the 
perspective of insulin resistance as beta-cell failure, and the ability of metformin to counter insulin 
resistance generated interest [54, 55].  New information in the 1980s and early 1990s indicated that 
the ability of metformin to reduce hepatic gluconeogenesis and increase peripheral glucose 
utilisation was not merely an anaerobic consequence of respiratory chain disruption [45].  Rather, 
metformin affected a raft of insulin-dependent and insulin-independent effects that vary in different 
tissues due to the amount of drug exposure to these tissues and the activity of insulin, glucagon and 
pathways of nutrient metabolism within these tissues. In particular it became evident that high 
levels of metformin in the intestinal wall exert insulin-independent effects that account for most of 
the extra lactate production, whereas liver and muscle are exposed to lower concentrations of 
metformin that alter post-receptor insulin signalling pathways and redirect energy-generating and 
storage pathways [56-62].   
Metformin enters the USA 
With reverberations from phenformin, the US Food and Drug Administration (FDA) was hesitant 
about metformin, but in 1986 an approach by Lipha Pharmaceuticals (having acquired Aron 
Laboratories) sparked an inordinately thorough reassessment of metformin by the FDA and the 
sponsor.  The Lipha team was headed by Dr Gerard Daniel, an inspired, meticulous and pragmatic 
physician reminiscent of Jean Sterne. Daniel worked tirelessly alongside another very accomplished 
physician, Dr Anita Goodman, to deliver answers to an avalanche of questions from the FDA [6].  This 
involved a proliferation of studies from Lipha Europe plus input from a group of independent clinical 
scientists (initially Reaven, DeFronzo and Bailey, later joined by Turner and Garber) who engaged 
with the FDA to design the clinical trials, discuss the data and consider the implications for routine 
clinical use in the USA [6, 56].  FDA approved metformin on 29 Dec 1994 and soon after its launch in 
the USA in 1995 new key trial data were published in the New England Journal of Medicine [63].  
These and subsequent clinical studies confirmed and extended the Edinburgh findings of two 
decades earlier, and the design of the metformin trials has provided a template for phase 3 
evaluation of subsequent glucose-lowering agents [63, 64].  Bristol Myers Squibb acquired US 
marketing rights to metformin and instigated an education programme of unprecedented 
proportion to facilitate safe introduction of the drug, emphasising its different mode of action to 
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sulphonylureas and the necessary cautions associated with renal impairment and hypoxaemic 
conditions. The value of this safety-first approach accorded with the FDA’s black box reminder in the 
product label, and played an important role to maintain the acknowledged safety profile of the drug 
[64].  As prescriber confidence grew, an extended release formulation of metformin was approved in 
2000 with reduced gastro-intestinal side effects [65, 66].  Also, new fixed-dose combinations of 
metformin with sulphonylureas and later with other classes of oral glucose-lowering agents became 
available, taking advantage of additive efficacy when combining agents with different modes of 
action [67]. The key difference from earlier European fixed-dose combinations was that the dosages 
were based around metformin as the primary component, with doses of the second agent tailored 
to complement the administration schedule for metformin and to minimise risk of hypoglycaemia 
[68].    
The UKPDS and long-term retrospective studies 
In 1998 the UKPDS revealed data from newly diagnosed type 2 diabetes patients receiving glucose-
lowering treatment for more than a decade.  This epic study which redefined the therapeutic 
strategy for management of type 2 diabetes noted that in addition to glucose-lowering, weight 
neutrality and low hypoglycaemia risk, long-term metformin therapy might reduce cardiovascular 
(CV) events and improve survival [69].  Reduced CV risk appeared to be largely independent of 
glucose-lowering efficacy, and attention is drawn to a substantial literature noting potentially 
advantageous effects of the drug on the macro- and micro-vasculature (Table 3) [70, 71].  
Interrogation of large databases that captured long-term treatment of type 2 diabetes consistently 
confirmed the reduced CV risk with metformin, and the 10-year follow-up of the UKPDS in 2008 
showed a continued CV benefit of early use of the drug [72-74].   
First-line pharmacological choice 
Many studies on the pharmacokinetics, pharmacodynamics, clinical efficacy and cellular mechanisms 
of metformin have informed a favourable benefit-risk and, alongside cost-effectiveness, have 
elevated this agent to preferred first-line glucose-lowering pharmacological therapy for type 2 
diabetes in major national and international treatment guidelines and algorithms [eg. 75-78].  
Metformin has become the most prescribed glucose-lowering therapy worldwide and it is now 
included in the WHO Essential Medicines List  [79]. A citizens’ petition in the USA prompted an 
update to the product label in 2016 to extend prescribing for patients with mild renal impairment.  
Overall, the prominent position of metformin reflects judicious prescribing, emphasising that 
contraindications should not be over-relaxed if the safety profile is to be retained (Table 4).   
Other indications 
Possible additional indications for metformin are under investigation.  Opportunities for use in type 
1 diabetes to improve glycaemic control and reduce insulin dose have been appreciated since the 
very first clinical studies [6, 80].   Several studies have affirmed the value of metformin to slow or 
prevent progression of IGT/IFG ‘prediabetes’ to type 2 diabetes, and several studies have suggested 
a place for metformin in gestational diabetes [81-83].   Various insulin resistant states where 
metformin has improved prognosis include polycystic ovary syndrome (PCOS), human 
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immunodeficiency virus (HIV)-associated lipodystrophy, acanthosis nigricans and possibly dementia-
type neurodegenerative disorders [84-87].   Reduced cancer risk was tentatively indicated in the 
UKPDS and has subsequently been identified in large database analyses, suggesting that metformin 
might protect against certain cancers in type 2 diabetes patients, notably in the bowel where drug 
exposure is high, and this has opened a whole new research arena [69, 88, 89].   Advances in 
pharmacogenomics may better inform responsiveness to metformin and effects on the gut 
microbiome, and animal studies have intriguingly noted anti-ageing effects of metformin [90, 91]. 
Some lessons 
There are endless generic lessons for medical research thinly disguised within the history of 
metformin.  With hindsight we are reminded that time spent searching early original literature can 
save valuable laboratory time, effort and money: vital clues can be concealed amidst throw-away 
observations in other areas of research, selecting and interpreting experimental models is 
fundamental, scrutiny within a drug class can reveal important differences, and we don’t have to 
know exactly how a drug works to reap benefit, but we do need to appreciate how to use it safely.    
Conclusion 
The awesome voyage of metformin from herbal beginnings to respected therapeutic agent has been 
turbulent. It was discovered, forgotten, rediscovered, re-purposed, rejected, rescued, exonerated 
and may have further secrets to reveal.   Each chapter has a cast of champions who helped it on its 
way, but the pivotal work of Jean Sterne stands aloft (Figure 5) [6, 56]. Metformin is unusual 
amongst pharmacotherapies as it does not appear to have a single mechanistic target: rather it 
counters insulin resistance and impacts metabolic, vascular and other physiological functions 
through multiple effects that are individually modest but collectively substantial.  The value of such a 
favourably versatile medication requires that the contraindications (especially renal and hypoxaemic 
restrictions) are respected and that further potential therapeutic opportunities are explored.  
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LEGENDS TO FIGURES 
Figure 1.  Galega officinalis (goat’s rue, French Lilac). 
Figure 2.  Structure of guanidine and related compounds. 
Figure 3.  Jean Sterne 1909-1997 (photograph courtesy of Christophe Pasik, Merck-Lipha 
Pharmaceuticals).  Jean Sterne trained in medicine in Paris and gained experience in diabetology 
with Francis Rathery at Hopital de la Pitie as well as taking specialisms in infectious diseases, 
cardiology, psychiatry and neurology. During the 2nd world war he was a battalion medic, taken 
prisoner, escaped to Morocco where he worked as a musician, and return to France to assist in the 
liberation of Toulouse. After several years back in Morocco directing the medicines unit at a hospital 
in Casablanca he took a position with Aron Laboratories in Suresnes in Paris in 1956 where he 
investigated guanidine derivatives with Denise Duval. The rest, as they say, is history.  At the end of 
an interview in 1996 Sterne commented “When I look back on my life, I definitely can say that I’ve 
served a purpose on earth.” Metformin is his testament [23].   
Figure 4.  Metformin (1,1-dimethylbiguanide hydrochloride) is a relatively planar hydrophilic 
molecule, monoprotonated at neutral pH with several tautomeric configurations. Oral doses of 500-
1000 mg of the standard immediate release tablet formulation are rapidly absorbed (Tmax ~2.5hr) in 
the small intestine (about 50% bioavailability), typically giving a Cmax ~2ug/mL and rarely >4ug/mL, 
with a steady state concentration range of 0.3-1.5 ug/mL.  Plasma protein binding is negligible and 
distribution is extensive (volume of distribution Vd usually 100-300L).  Metformin has an elimination 
t1/2 of ~6-7 hours, longer if renal function is impaired: it is not metabolised and is excreted in the 
urine unchanged, about 20% is filtered and about 80% is secreted by the kidney [92].  
Figure 5.  Gallery of people who made metformin happen.  Upper row: Jean Sterne, Denise Duval, 
Jan Aron, Elie Azerad, Leslie Duncan, Basil Clarke, Ian Campbell, Leif Sparre Hermann, Harry Howlett, 
Michel Noel.  Lower row: Andre Meynaud, Nicolas Wiernsperger, Gerard Daniel, Anita Goodman, 
Gerald Reaven, Ralph DeFronzo, Clifford Bailey, Robert Turner, Alan Garber, Dennis Cryer, Rury 
Holman.  Missing: Watanabe, Werner & Bell, Hesse & Taubmann, Slotta & Tschesche, Eusebio 
Garcia.  Apologies to the thousands of scientists, healthcare professionals and pharmaceutical 
personnel listed in reference 56 who have made important contributions to the journey of 
metformin. 
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Table 1.  Landmark events in the history of metformin for the management of type 2 diabetes. 
Year Landmark Reference 
1772 Galega officinalis used to treat symptoms of diabetes (Hill) 3 
1844-61 Identification and synthesis of guanidine (Strecker) 6 
1878-9 Synthesis of biguanide (Rathke) 6 
1918 Guanidine lowers blood glucose in animals (Watanabe) 7 
1922 Synthesis of dimethyl biguanide (Werner and Bell) 17 
1926-8  Galegine and synthalin lower blood glucose in animals and humans  8-13 
1929  Metformin and other biguanides lower blood glucose in animals (Hesse and 
Taubmann; Slotta and Tschesche)   
18,19 
1930s Use of guanidine derivatives to treat diabetes initially grows then declines 
due to toxicity and availability of insulin 
6 
1944-7 Guanidine-based antimalarial agent - proguanil (paludrine) lowers blood 
glucose in animals 
20, 21 
1949-50 Dimethyl biguanide (Flumamine) tested as potential anti-malarial agent and 
used to treat influenza in Philippines: may lower blood glucose (Garcia)  
22 
1956 Jan Aron encourages Jean Sterne and Denise Duval to study guanidine-based 
glucose-lowering agents  
6 
1957 Jean Sterne publishes use of metformin to treat diabetes 24 
1957-9 Phenformin and buformin reported as treatments for diabetes 32, 33, 
37, 38 
1958 Metformin introduced to treat diabetes in UK and other European countries  6 
1958-64 Sterne and colleagues further evaluate metformin in diabetic patients 25-28,36 
1968 First large prospective comparator trial of metformin (Edinburgh group) 42 
1977-80 Phenformin and buformin withdrawn in most countries due to risk of lactic 
acidosis  
49 
1994 Metformin approved in USA and introduced in USA in 1995 6 
1995-6 Key publications confirm favourable benefit-risk of metformin in 
management of type 2 diabetes  
63, 64 
1998 United Kingdom Prospective Diabetes Study (UKPDS) reports long-term 
metabolic effects of metformin and reduced cardiovascular risk 
69 
2000-2 Extended release formulation and fixed-dose combination based on 
metformin as primary active ingredient approved in USA 
65,67 
2002 Metformin reduced progression of ‘prediabetes’ to type 2 diabetes in 
Diabetes Prevention Program (DPP) 
79 
2005 International Diabetes Federation recommends metformin as initial glucose-
lowering pharmacotherapy for type 2 diabetes.  Other guidelines adopt 
metformin as initial glucose-lowering agent. 
75 
2008 UKPDS follow-up: continued reduction of cardiovascular risk with metformin 74 
2011 Metformin included in WHO Essential Medicines List    79 
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Table 2. Some differences between metformin, phenformin and buformin.  
Feature Metformin Phenformin Buformin 
Solubility 
Log P (octanol/water) 
More hydrophilic 
-1.43 
More lipophilic  
-0.83 
More lipophilic  
-1.2 
Binding to mitochondrial 
membranes and inhibition 
of respiratory chain 
Weaker  Stronger Stronger 
Anaerobic glycolysis  Intestinal tissue exposed 
to high drug concentration 
More generalised, 
including muscle 
More generalised, 
including muscle  
Metabolism Not metabolised, 
eliminated unchanged  
About 1/3rd hydroxylated 
by CYP2D6 (~9% Europids 
have 2D6 polymorphisms) 
Almost all 
unchanged  
Risk of lactic acidosis per 
1,000 patient years 
0.03-0.09 0.4-0.9 >0.1 
  
Based on references 40, 45, 92.   
 
 
Table 3.  Pharmacodynamic effects of metformin in the treatment of type 2 diabetes  
Clinical feature                                         Effect of metformin 
Hyperglycaemia Improves glycaemic control in type 2 diabetes; reduces progression of 
impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) to 
type 2 diabetes.  
Insulin resistance Counters insulin resistance by several insulin-dependent and independent 
actions that reduce hepatic glucose output, improve peripheral glucose 
disposal, increase intestinal anaerobic glucose metabolism and assist 
endothelial function 
Hyperinsulinaemia  Reduces fasting hyperinsulinaemia 
Abdominal obesity Usually stabilizes body weight; can facilitate reduction of excess adiposity 
Dyslipidaemia  May modestly improve blood lipid profile in some hypertriglyceridaemic 
and hypercholesterolaemic individuals 
Blood pressure   No significant effect on blood pressure in most studies but blood pressure 
control may be improved in overweight individuals achieving weight loss 
Pro-inflammatory state   May reduce C-reactive protein and some adipo-cytokines 
Pro-coagulant state Some anti-thrombotic activity eg. decreases in PAI-1, fibrinogen and 
platelet aggregation; improved capillary perfusion 
Atherosclerosis Reduced myocardial infarction and increased survival in type 2 diabetes:  
reduced carotid intima-media thickness and reduced adhesion molecules; 
other evidence for anti-atherogenic activity, mostly from  animal studies 
PAI, plasminogen activator inhibitor 
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Table 4.   Clinical use of metformin in the treatment of type 2 diabetes.  
Feature Comment 
Indicationsa Monotherapy or in combination with other glucose-lowering agents 
including  insulin in type 2 diabetes patients inadequately controlled by 
diet, exercise, and health education 
Dosage formsb 500-, 850-, and 1,000-mg standard (IR) tablets: taken with meals               
500-, 750-, and 1,000-mg XR tablets: mostly taken with evening meal 
500mg/5mL liquid formulation and 500mg sachets of powder 
Titration Increase dose slowly; monitor glycaemic control; maximal dose 2,550 or 
3,000 mg/day depending on country (2,000 mg/day in children)  
Contraindicationsa Renal and hepatic disease; cardiac or respiratory insufficiency; any 
hypoxic condition; severe infection; alcohol abuse; history of lactic 
acidosis;  temporarily discontinue during use of intravenous 
radiographic contrast agents; pregnancy (although safe use 
demonstrated in several studies)  
Some guidelines have relaxed the renal contraindication and suggest 
metformin dose reduction in renal impairment if eGFR <60 
ml/min/1.73m2 (MDRD), avoid initiating metformin if eGFR <45 
ml/min/1.73m2 and stop metformin if eGFR <30 ml/min/1.73m2 
Side effects Gastrointestinal symptoms (may include diarrhoea) and metallic taste, 
likely to improve with dose reduction and re-titration; may impair 
absorption of vitamin B12 and folic acid  
Adverse reactions Risk of lactic acidosis in patients with a contraindication; hypoglycaemia 
can occur when taken in combination with another glucose-lowering 
drug or during alcohol abuse  
Monitoring Check for contraindications; check plasma creatinine or eGFR and 
haemoglobin periodically; possible interaction with cimetidine therapy 
 
IR, immediate release; XR, extended release (called SR – slow release in some countries); eGFR 
estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease 
a exact wording of indications and contraindications varies according to labelling approved in 
different countries and regional and national guidelines 
b availability of dose and formulation varies with country  
